NSABPB35_2: NSABPB35, figure 2

NSABPB35_2R Documentation

NSABPB35, figure 2

Description

Kaplan-Meier digitized data from NSABPB35, figure 2 (PMID 26686957). A reported sample size of 3,104 for a primary endpoint of BCFS in breast cancer.

Usage

NSABPB35_2

Format

A data frame of 3,077 observations and 3 variables:

time event time (in months)
event EFS event indicator (0: no event, 1: event)
arm treatment arms (anastrazole, tamoxifen)

Source

Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 2016; 387: 849–56.

Examples

summary(NSABPB35_2)

kmplot(NSABPB35_2)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.